BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36869126)

  • 21. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.
    Shuai S; Liao X; Wang H; Liu L; Mei S; Cao J; Wang S
    Cancer Sci; 2021 Oct; 112(10):4139-4150. PubMed ID: 34058054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
    Xiao Z; Li M; Zhang X; Rong X; Xu H
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SOX9 promotes epidermal growth factor receptor-tyrosine kinase inhibitor resistance via targeting β-catenin and epithelial to mesenchymal transition in lung cancer.
    Tripathi SK; Biswal BK
    Life Sci; 2021 Jul; 277():119608. PubMed ID: 33989664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
    Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.
    Guo H; Zhang X; Xie S; Chen T; Xie D; Cai Y; Cui D; Wang L; Chen W; Wang X
    Int J Oncol; 2022 Dec; 61(6):. PubMed ID: 36205136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
    Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
    PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Caffeic acid phenethyl ester surmounts acquired resistance of AZD9291 in non-small cell lung cancer cells.
    Twum Y; Marshall K; Gao W
    Biofactors; 2023; 49(6):1143-1157. PubMed ID: 37555475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
    Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
    Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
    Meng S; Wang G; Lu Y; Fan Z
    Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DACT2 modulated by TFAP2A-mediated allelic transcription promotes EGFR-TKIs efficiency in advanced lung adenocarcinoma.
    Zhang N; Li Y; Xie M; Song Y; Liu J; Lei T; Shen Y; Yu J; Yang M
    Biochem Pharmacol; 2020 Feb; 172():113772. PubMed ID: 31866302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serine-arginine protein kinase 1 promotes a cancer stem cell-like phenotype through activation of Wnt/β-catenin signalling in NSCLC.
    Gong L; Song J; Lin X; Wei F; Zhang C; Wang Z; Zhu J; Wu S; Chen Y; Liang J; Fu X; Lu J; Zhou C; Song L
    J Pathol; 2016 Oct; 240(2):184-96. PubMed ID: 27391422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells.
    Fujiwara R; Taniguchi Y; Rai S; Iwata Y; Fujii A; Fujimoto K; Kumode T; Serizawa K; Morita Y; Espinoza JL; Tanaka H; Hanamoto H; Matsumura I
    Biochem Biophys Res Commun; 2022 Oct; 626():156-166. PubMed ID: 35994825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
    Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer.
    Huang Q; Wang Q; Li D; Wei X; Jia Y; Zhang Z; Ai B; Cao X; Guo T; Liao Y
    J Exp Clin Cancer Res; 2019 Mar; 38(1):129. PubMed ID: 30876460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.
    Hu H; Miao XK; Li JY; Zhang XW; Xu JJ; Zhang JY; Zhou TX; Hu MN; Yang WL; Mou LY
    Eur J Pharmacol; 2020 May; 874():172961. PubMed ID: 32044322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.